Update on genistein and thyroid: an overall message of safety

Frontiers in Endocrinology

Endocrinology

Salvatore Benvenga¹  Francesco Squadrito²  Alessandra Bitto²  Elena B. Adamo³  Francesca Polito³  Herbert Marini³ 

[1] Section of Endocrinology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina,, Messina, Italy;Master on Childhood, Adolescent and Women’s Endocrine Health, University of Messina,, Messina, Italy;Interdepartmental Program of Molecular and Clinical Endocrinology, and Women’s Endocrine Health, University Hospital of Messina,, Messina, Italy;Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina,, Messina, Italy;Section of Physiology and Human Nutrition, Department of Biochemical, Physiological and Nutritional Sciences, University of Messina,, Messina, Italy;

关键词: genistein;    isoflavones;    soy;    safety;    thyroid;   

DOI  :  10.3389/fendo.2012.00094

 received in 2012-02-10, accepted in 2012-07-16,  发布年份 2012

来源: Frontiers

【 摘 要 】

Genistein aglycone, one of the soy isoflavones, has been reported to be beneficial in the treatment of menopausal vasomotor symptoms, osteoporosis, and cardiovascular diseases, as well as in a variety of cancers. However, issues of potential harm on thyroid function resulting from soy isoflavones consumption have been raised. Much of the evidence for the goitrogenic effects of isoflavones is derived from experimental in vitro and in vivo studies. Goitrogenic effects were also noted in infants fed non-iodine-fortified, soy-based formula, a problem that was easily solved with iodine fortification. Recent studies suggest that genistein shows a good profile of safety on the thyroid although definitive conclusions have not reached. The aim of this brief review is to summarize and better clarify the effects of genistein on human thyroid health.

【 授权许可】

Unknown   
Copyright © Marini, Polito, Adamo, Bitto, Squadrito and Benvenga.